A novel anti‐inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology

A novel anti‐inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin... Summary There is a need for safe and effective therapies for inflammatory skin diseases. Current topical and systemic treatment of psoriasis is effective but suffers from side‐effects or is inconvenient. The therapeutic armamentarium for atopic dermatitis is very limited and far from satisfactory. In vivo preclinical data are presented for SDZ ASM 981, a novel ascomycin macrolactam derivative with high anti‐inflammatory activity. Anti‐inflammatory activity was observed in mouse, rat and pig models of allergic contact dermatitis. In the pig model, topical SDZ ASM 981 was as effective as the ultrapotent corticosteroid clobetasol‐17‐propionate, and when compared with a series of commercial topical corticosteroid preparations, 0·1% SDZ ASM 981 had equivalent efficacy to clobetasol‐17‐propionate (0·05%), the most potent product on the market. Unlike the corticosteroid, however, SDZ ASM 981 did not cause skin atrophy in pigs. SDZ ASM 981 potently inhibited allergic contact dermatitis in mice and rats when given systemically, and oral treatment was more effective than cyclosporin A in rats. Furthermore, SDZ ASM 981 has a low potential for affecting systemic immune responses, as demonstrated in rat models of localized graft vs. host reaction and allogeneic kidney transplantation. Preclinical results suggest that SDZ ASM 981 has the potential to be a well‐tolerated and effective drug for topical as well as oral treatment of inflammatory skin diseases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Dermatology Wiley

A novel anti‐inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology

Loading next page...
 
/lp/wiley/a-novel-anti-inflammatory-drug-sdz-asm-981-for-the-topical-and-oral-U0kyBI0kgx
Publisher
Wiley
Copyright
Copyright © 1997 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0007-0963
eISSN
1365-2133
DOI
10.1111/j.1365-2133.1997.tb03788.x
Publisher site
See Article on Publisher Site

Abstract

Summary There is a need for safe and effective therapies for inflammatory skin diseases. Current topical and systemic treatment of psoriasis is effective but suffers from side‐effects or is inconvenient. The therapeutic armamentarium for atopic dermatitis is very limited and far from satisfactory. In vivo preclinical data are presented for SDZ ASM 981, a novel ascomycin macrolactam derivative with high anti‐inflammatory activity. Anti‐inflammatory activity was observed in mouse, rat and pig models of allergic contact dermatitis. In the pig model, topical SDZ ASM 981 was as effective as the ultrapotent corticosteroid clobetasol‐17‐propionate, and when compared with a series of commercial topical corticosteroid preparations, 0·1% SDZ ASM 981 had equivalent efficacy to clobetasol‐17‐propionate (0·05%), the most potent product on the market. Unlike the corticosteroid, however, SDZ ASM 981 did not cause skin atrophy in pigs. SDZ ASM 981 potently inhibited allergic contact dermatitis in mice and rats when given systemically, and oral treatment was more effective than cyclosporin A in rats. Furthermore, SDZ ASM 981 has a low potential for affecting systemic immune responses, as demonstrated in rat models of localized graft vs. host reaction and allogeneic kidney transplantation. Preclinical results suggest that SDZ ASM 981 has the potential to be a well‐tolerated and effective drug for topical as well as oral treatment of inflammatory skin diseases.

Journal

British Journal of DermatologyWiley

Published: Oct 1, 1997

References

  • Consensus conference on cyclosporin A for psoriasis, February 1992
    Mihatsch, Mihatsch; Wolff, Wolff
  • Short‐term use of cyclosporin A in severe psoriasis
    Joost, Joost; Heule, Heule; Stolz, Stolz; Beukers, Beukers

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off